Prior Authorization for Ustekinumab Dose Escalation Negatively Affects Outcomes in Patients With Inflammatory Bowel Disease

Abstract

Get full access to this article

View all access options for this article.

References

Fedorak

Kaplan

, et al. Long-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in moderate-to-severe Crohn’s disease: real-world experience from a multicenter cohort study. Inflamm Bowel Dis. 2017;23(5):833-839. doi:10.1097/MIB.0000000000001074.

Ollech

Normatov

Peleg

, et al. Effectiveness of ustekinumab dose escalation in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2021;19(1):104-110. doi:10.1016/j.cgh.2020.02.035.

Khorrami

Ginard

Marín-Jiménez

, et al. Ustekinumab for the treatment of refractory Crohn’s disease: the Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016;22(7):1662-1669. doi:10.1097/MIB.0000000000000842.

Resneck

JS.

Refocusing medication prior authorization on its intended purpose. JAMA. 2020;323(8):703-704. doi:10.1001/jama.2019.21428.